Reimagining healthcare access and delivery
Bert Vorstman, MD, Ron Piana, David Hartmann
by Bert Vorstman | Nov 13, 2024 | Health insurance alternatives, health insurance restricts access and choice, Health Insurances, Healthcare, Healthcare costs, HEALTHdrum, Insurance, No health insurance, Price Transparency, Prostate cancer, Women's health
The World Health Organization states that patients have the right to access healthcare according to his or her own judgment. In sharp contrast, the health insurance industry has created innumerable self-serving barriers that severely limit the ability of patients to...
Enhancing employee wellbeing
by Bert Vorstman | Jun 29, 2023 | Healthcare, HEALTHdrum, Prostate cancer
In today’s fast-paced and competitive business landscape, companies are increasingly recognizing the importance of employee well-being as a key driver of productivity, engagement, and talent retention. One innovative approach that has garnered attention is...
Two great books underscoring the many dangers in the prostate cancer arena
by Bert Vorstman | Aug 1, 2022 | Prostate cancer
Prostate cancer detection and treatment remain very controversial subjects. However, there are two earth-shattering books packed with facts that will empower you so you don’t become another sorry statistic injured during the prostate cancer testing and treatment...
Is prostate cancer surgery licensed medical malpractice?
by Bert Vorstman | Jun 25, 2022 | Prostate cancer
Robotic prostatectomy remains a very controversial procedure – even amongst urologists. Prostate cancer surgery had its origins over 100 years ago when experimental trial and error surgery was permitted. In the 1980s this treatment philosophy for prostate cancer...
by Bert Vorstman | Jun 18, 2022 | Prostate cancer
Patients with prostate cancer have a right to expect that their screening, diagnosis, and treatment are supported by evidence-based science. But how well does the urology community measure up when it comes to claims that standard-of-care practices are evidence-based?...
When doctors stray from science into junk science
Bert Vorstman, MD
by Bert Vorstman | May 25, 2022 | Prostate cancer
PSA testing and prostate cancer management remain controversial. In recognition of the fact that many prostate cancer treatments are harmful and that many low-risk prostate cancers can be outlived without intervention, a less hurried active surveillance program was...